Novel variants in *AP4B1* cause spastic tetraplegia, moderate psychomotor development delay and febrile seizures in a Chinese patient: a case report

Wen-Cong Ruan1, Jia Wang2, Yong-Lin Yu1, Yue-Ping Che1, Li Ding1, Chen-Xi Li1, Xiao-Dong Wang2* and Hai-Feng Li1*

**Abstract**

**Introduction:** The *AP4B1* gene encodes a subunit of adaptor protein complex-4 (AP4), a component of intracellular transportation of proteins which plays important roles in neurons. Bi-allelic mutations in *AP4B1* cause autosomal recessive spastic paraplegia-47 (SPG47).

**Case presentation:** Here we present a Chinese patient with spastic tetraplegia, moderate psychomotor development delay and febrile seizures plus. Brain MRIs showed dilated supratentorial ventricle, thin posterior and splenium part of corpus callosum. The patient had little progress through medical treatments and rehabilitating regimens. Whole exome sequencing identified novel compound heterozygous truncating variants c.1207C > T (p.Gln403*) and c.52_53delAC (p.Cys18Glnfs*7) in *AP4B1* gene. Causal mutations in *AP4B1* have been reported in 29 individuals from 22 families so far, most of which are homozygous mutations.

**Conclusions:** Our study enriched the genetic and phenotypic spectrum of SPG47. Early discovery, diagnosis and proper treatment on the conditions generally increase chances of improvement on the quality of life for patients.

**Keywords:** Spastic tetraplegia, Sequencing, Mutation, Rehabilitation
psychomotor development delay, and febrile seizures plus (FS). The conditions were improved through several years of rehabilitation.

**Case presentation**

**Clinical presentation**

Patient is a 9-year-old boy born to non-consanguineous healthy parents. He was born at 40 weeks of gestation by natural delivery. The birth weight was 3.4 kg. Apgar scores were 10–10 – 10. There was no special medical history during pregnancy, and no perinatal complications were noticed. He was able to hold up his head firmly at 3 months, roll over at 6 months, sit uprightly on his own at 10 months, stand unaidedly at 20 months, and walk well at 2-year-old. He began to speak a few words at 2 years old, such as “baba”, “mama”.

He was admitted to the hospital at the age of 9 months for sitting unstably without assistance. The psychomotor developmental delay was noticed. Long-term local rehabilitation started immediately. During the time, he had a seizure triggered by fever. The conditions, including upward rolling of the eyes, lips cyanosis, tonic stiffening of the upper limbs and lacking of consciousness, lasted for almost 10 mins. He was diagnosed as febrile seizures plus (FS+) by his physician in local hospital. The patient was treated with oral administration of topiramate tablets for 3 months (dosage unknown). However, he suffered recurrent febrile seizures (2~3 times /year, lasting 2 to 10 min each time) with the same manifestations. At the age of 6, he was given 0.1 ml/kg (Bid) of oral solution of levetiracetam (100 mg/ml). One year later, seizures occurred again, but had been controlled with adjusted dosage to12.5 mg/kg (Bid) of levetiracetam tablets.

![MRI scan results](image)

**Fig. 1** MRI scan results of patient presented unstable walk with lisping at seven-year-old and was referred to a pediatric neurologist at the 7-year-old (201702). a Brain MRIs showed dilated supratentorial ventricle. b Thin posterior part and splenium of corpus callosum. c Total spine MR imaging suggested 1, L4, 5 recessive spina bifida. d Cervical and thoracic spinal cord scan was normal. e Lumbosacral segment of spinal cord scan was normal. f Pelvic radiograph was normal.
The patient presented unstable walk with lisping at seven-year-old. He was referred to a pediatric neurologist. His physical examination results were described as following: he could communicate and express his needs in simple words with a lisp; he could stand and walk without support, jump on both feet, and stand on one foot for a while. However, he could neither jump on one foot nor run. He appeared lumbar lordosis, pelvic tilt, hip flexion, foot valgus, insufficient camptodactyly of ankle when walking alone, bilateral babinski sign (+), and ankle clonus (+).

Brain MRIs showed dilated supratentorial ventricle (Fig. 1a), thin posterior and splenium part of corpus callosum (Fig. 1b). Total spine MR imaging suggested 1, L4, 5 recessive spina bifida (Fig. 1c). Cervical, thoracic, and lumbosacral segment of spinal cord scan, pelvic radiograph, and electromyography were all normal (Fig. 1d-f). Recessive spina bifida was the result of full (or lateral) splicing of the spine, and tethered spinal cord syndrome was excluded. No apparent changes were found from laboratory tests of blood routine, blood biochemistry, blood genetic metabolic mass spectrometry and thyroid functional indices.

Molecular studies
We performed Whole Exome Sequencing on the patient in order to identify the disease-causing variants. The exomes were captured from peripheral blood DNA using Agilent SureSelectV6 kit and sequenced by Illumina HiSeq4000 (Paired-end). Data processing, alignment (using a Burrows-Wheeler algorithm, BWA-mem) and variant calling were performed using Genome Analysis Tool Kit (GATK v4) best practices (https://software.broadinstitute.org/gatk/best-practices/) from the Broad Institute. Variant annotation was done using ANNOVAR (http://www.openbioinformatics.org/annovar/). Variants were picked up in exonic and splicing regions with a minor allelle frequency of ≤0.005 in SNP database (ExAC_EAS, ExAC_ALL, 1000Genomes, gnomAD). The identified variants were confirmed and segregation analysis of the two variants from parents was applied by Sanger sequencing.

We detected two heterozygous truncating variants (c.1207C > T (p.Gln403*), c.52_53delAC (p.Cys18Glnfs*7)) in AP4B1(NM_001253852.2) from patient (Fig. 2). His parents were heterozygous carriers. The patient inherited c.1207C > T allele from his father and c.52_53delAC from his mother. Both variants were suggested to be pathogenic according to the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG-AMP) variant interpretation guidelines [9]. These compound heterozygous truncating variants were considered to be disease-causing in the boy with the clinical symptoms of spastic tetraplegia, moderate psychomotor development delay and febrile seizures plus.

The boy started on rehabilitating program with physical therapy on regular basis. The detailed regimens were as following: kinesitherapy (30 min/time, 4 times/week), sling exercise therapy (30 min/time, 2 times/week), continue passive motion (20 min/time, 4 times/week). Joint stretching, joint activity training and progressive resistance training were mainly used to enhance the separation of the lower limbs, core muscles and the lower limbs-pelvis-toro. They were also used to correct the abnormal gait (Fig. 3). In addition, psycho-social support was also an

Fig. 2 Whole-exome sequencing (WES) and Sanger sequencing revealed compound heterozygous truncating variants c.1207C > T (p.Gln403*), c.52_53delAC (p.Cys18Glnfs*7)) in AP4B1(NM_001253852.2). Electrocromatograms illustrated the variants in patient (arrow) and his parents. wt, wildtype
important part of the treatment. He showed significant improvement after 2 years of program judging by the angle changes of dorsiflexion, popliteal fossa, and adductors as well as the evaluation data on Gross Motor Function Measure (GMFM) (Table 1). An improvement on active and passive foot dorsiflexion angle, popliteal fossa angle, and adductor angle reflected the progress of limb function in patient (Table 1). The increase in GMFM score suggested that the patient's gross motor function has not regressed (in theory), but progressed continuously over time, proving the effectiveness of treatment.

**Discussion and conclusions**

We reported a patient with spastic tetraplegia, moderate psychomotor development delay and febrile seizures plus-. A paternal heterozygous nonsense variant c.1207C > T (p.Gln403*) and a maternal heterozygous frameshift variant c.52_53delAC (p.Cys18Glnfs*7) which resulted in the introduction of a premature termination codon in two different alleles were identified in AP4B1 gene. Ebrahimi-Fakhari et al [5] reported the clinical and genetic characterization of nineteen probands with AP4B1-associated SPG47 including early developmental delay and intellectual disability(100%), delayed motor development(100%), neonatal or infantile hypotonia(100%), delayed speech development(94%), progression to spastic diplegia (89%), loss of independent walking (88%), short stature (57%), thin corpus callosum(73%), delayed myelination or white matter loss(67%), ventriculomegaly(40%). Only half of the patients had epilepsy (47%), especially febrile seizures (3/19). Symptoms of the patient we reported here were consistent with the clinical characterizations of patients reported previously. Accogli et al. [6] reported another SPG47-related child who was admitted to the hospital at the age of 14 months. The child had an afebrile generalized tonic-clonic epilepticus status which required resuscitation. Our patient, who had been diagnosed as febrile seizures plus, had afebrile seizures more than 2 times before developing typical febrile seizures. He also continued febrile seizures beyond the age of 6 years. This condition was a relatively rare feature reported before.

**AP4** is a heterotetrameric adaptor protein which composed of two large subunits, beta-4 (AP4B1) and epsilon-4 (AP4E1), one medium protein, mu-4 (AP4M1), and one small protein, sigma-4 (AP4S1)(10). Besides of AP4B1, mutations on other three subunits can also cause autosomal recessive-HSPs. Homozygous or compound heterozygous mutations in AP4M1 result in autosomal recessive spastic paraplegia-50 (SPG50, MIM:612936) is characterized by neonatal hypotonia that progresses to hypertonia and spasticity and severe mental retardation with poor or absent speech development [10, 11]. AP4E1 and AP4S1 are related to SPG51 (MIM:613744) and SPG52 (MIM:614067) respectively with the similar

**Table 1** Examination of rehabilitation effects

|                  | 201705 | 201709 | 201801 | 201906 |
|------------------|--------|--------|--------|--------|
| **Dorsiflexion Angle** (active) |        |        |        |        |
| left             | −10°   | 0°     | 0°     | 25°    |
| Right            | −10°   | 0°     | 0°     | 15°    |
| **Dorsiflexion Angle** (passive) |        |        |        |        |
| left             | −5°    | 15°    | 15°    | 45°    |
| Right            | −5°    | 15°    | 15°    | 25°    |
| **Popliteal fossa Angle** |        |        |        |        |
| left             | 90°    | 90°    | 97°    | 100°   |
| Right            | 85°    | 90°    | 95°    | 100°   |
| **Adductors Angle** |        |        |        |        |
| left             | 80°    | 90°    | 90°    | 105°   |
| **GMFM** | 82.13  | 84.96  | 86.45  | 90.58  |

*a GMFM Gross Motor Function Measure
b Date for physical test
symptoms [4, 12, 13]. Hardies et al. [14] reported two sisters, born of unrelated Caucasian parents, who showed clinical features including developmental delay, febrile seizures, and spastic paraplegia caused by AP4S1. The older sister had five brief generalized febrile seizures between 5 months and 5 years of age whose manifestation was similar to our patient.

Totally, twenty-two mutants in AP4B1 have been reported including the ones from our patient (Supp Table 1). Homozygous mutations c.304C > T (p.Arg102*) and c.664delC (p.Leu222Cysfs*31) are the most frequently detected variants from consanguineous families. The allele counts are 10 for each of two mutations from 30 patients (Fig. 4). The vast majority of pathogenic variants identified so far are truncating variants (allele counts ratio is 52/60) which can often be assumed to disrupt gene function by leading to a complete absence of the gene product by nonsense-mediated decay of an altered transcript or lack of transcription (e.g. nonsense, frameshift, canonical splice site).

The patient has little progress through medications and rehabilitations. His seizures are well controlled by adjusted medication of anti-epileptic drug, 12.5 mg/kg (Bid) of levetiracetam tablets. He remained seizure-free for more than 2 years. No apparent regression had been seen in patient’s motor development by physical therapy, including joint stretching, joint activity training and progressive resistance training. His speech and language development had been severely delayed for a long time. He could speak a few words (“baba”, “mama”) until 2-year-old. We thought it might have a relationship with seizures to some extent, therefore, we paid more attention to anti-epileptic treatment clinically. For language and speech impairment, the hospital’s teaching and parent intervention methods were used due to the need to protect the children’s other daily activities. Our department keeps on providing follow-up care at home regularly and adjusting the guidance program according to the situation of patient. He is supported and cared by relatives, friends as well as the whole society.

In conclusion, in this report we identified two novel pathogenic variants from a Chinese patient with clinical features of hereditary spastic paraplegias, including spastic tetraplegia, moderate psychomotor development delay and febrile seizures plus. Our findings expanded the knowledge of genotypic and phenotypic heterogeneity and similarity of HSPs. Early discovery, diagnosis and proper treatment on the conditions generally increase chances of improvement on the quality of life for patients.

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s12881-020-0988-3.

**Additional file 1: Supplemental Table1.** Mutants in AP4B1 gene collected in research papers.

**Abbreviations**

ACMG-AMP: American College of Medical Genetics and Genomics and the Association for Molecular Pathology; FS: Febrile seizures; GMFM: Gross Motor Function Measure; HSPs: Hereditary spastic paraplegias; SPG47: Autosomal recessive spastic paraplegia-47

**Acknowledgements**

We thank the patient and his parents for participating in this study.

**Authors’ contributions**

WCR, HFL proposed the meaning and concept of the study and designed the plan for the case. WCR, YLY, YPC, LD, CXL made contributions to data collection and analysis. WCR, JW, HFL, XDW drafted and revised the manuscript. All of the authors read and approved the final manuscript to be published and agreed to be responsible for the accuracy of the data and details.

**Funding**

This work was supported by The National Key Research and Development Program of China of the 13th Five-Year Plan (No.2016YFC1306205); the provincial key disciplines of Zhejiang traditional Chinese medicine (combination of traditional Chinese and Western medicine) (No.2017-XK-A11); Technological Research Program of Zhejiang (2015C33178) made contributions to the design of the study, data collection and analysis.

**Availability of data and materials**

The datasets generated during the current study are available in NCBI SRA, under the accession number "SRR11117837".
Ethics approval and consent to participate
Written informed consent was obtained from both the patient's legal guardian (his parents) to participate in this study. This study was approved by the human ethics committees of The Children’s Hospital, Zhejiang University School of Medicine.

Consent for publication
Written informed consent was obtained from both the patient’s legal guardian (his parents) for the publication of the details and genetic sequencing of the case report.

Competing interests
The authors declare that they have no competing interests.

Received: 5 November 2019 Accepted: 28 February 2020
Published online: 14 March 2020

References
1. Klebe S, Stevanin G, Depienne C. Clinical and genetic heterogeneity in hereditary spastic paraplegias: from SPG1 to SPG72 and still counting. Rev Neurol (Paris). 2015;171(6-7):505–30. Available from: https://doi.org/10.1016/j.neurol.2015.02.017.
2. Dell’Angelica EC, Mullins C, Bonifacino JS. AP-4, a novel protein complex related to clathrin adaptors. J Biol Chem. 1999;274(1):7278–85.
3. Hirst J, Bright NA, Rous B, Robinson MS. Characterization of a fourth adaptor-related protein complex. Mol Biol Cell. 1999;10(8):2787–802.
4. Abou Jamra R, Philippe O, Raas-Rothschild A, Eck SH, Graf E, Buchert R, et al. Adaptor protein complex 4 deficiency causes severe autosomal-recessive intellectual disability, progressive spastic paraplegia, shy character, and short stature. Am J Hum Genet. 2011;88(6):788–95.
5. Ebrahimi-Fakhari D, Cheng C, Dies K, Diplock A, Pier DB, Ryan CS, et al. Clinical and genetic characterization of AP4B1-associated SPG47. Am J Med Genet Part A. 2018;176(2):311–8.
6. Accogli A, Hamdan FF, Poulin C, Nassif C, Rouleau GA, Michaud JL, et al. A novel homozygous AP4B1 mutation in two brothers with AP-4 deficiency syndrome and ocular anomalies. Am J Med Genet Part A. 2018;176(4):985–91.
7. Hebbal M, Shukla A, Nampoothiri S, Belas S, Girisha KM. Locus and allelic heterogeneity in five families with hereditary spastic paraplegia. J Hum Genet [Internet]. 2019;64(1):17–21. Available from:. https://doi.org/10.1038/s10038-018-0523-y.
8. Helbig KL, Farwell Hagman KD, Shinde DN, Mroske C, Powis Z, Li S, et al. Diagnostic exome sequencing provides a molecular diagnosis for a significant proportion of patients with epilepsy. Genet Med. 2016;18(9):988–905.
9. Richards CS, Bale S, Bellissimo DR, Das S, Grody WW, Hegde MR, et al. ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med. 2008;10(4):294–300.
10. Tüysüz B, Bilgiclar K, Köçer N, Yalçınkaya C, Çağlayan O, Gül E, et al. Autosomal recessive spastic tetraplegia caused by AP4M1 and AP4B1 gene mutation: expansion of the facial and neuroimaging features. Am J Med Genet Part A. 2014;164(7):1677–85.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.